vs
CS Disco, Inc.（LAW）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
CS Disco, Inc.的季度营收约是REGENXBIO Inc.的1.4倍（$41.2M vs $30.3M），CS Disco, Inc.净利率更高（-20.7% vs -221.3%，领先200.7%），REGENXBIO Inc.同比增速更快（43.0% vs 11.3%），CS Disco, Inc.自由现金流更多（$255.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.6%）
CS Disco, Inc.是一家领先的法律科技企业，开发面向法律从业者的云原生软件产品，涵盖电子取证、文档审核、案件管理及法律工作流自动化等工具，服务客户包括律师事务所、企业法务部门及政府法律机构。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LAW vs RGNX — 直观对比
营收规模更大
LAW
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出31.7%
11.3%
净利率更高
LAW
高出200.7%
-221.3%
自由现金流更多
LAW
多$53.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $30.3M |
| 净利润 | $-8.5M | $-67.1M |
| 毛利率 | 75.1% | — |
| 营业利润率 | -22.4% | -190.0% |
| 净利率 | -20.7% | -221.3% |
| 营收同比 | 11.3% | 43.0% |
| 净利润同比 | 66.3% | -31.2% |
| 每股收益（稀释后） | $-0.13 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LAWRGNX
| Q4 25 | $41.2M | $30.3M | ||
| Q3 25 | $40.9M | $29.7M | ||
| Q2 25 | $38.1M | $21.4M | ||
| Q1 25 | $36.7M | $89.0M | ||
| Q4 24 | $37.0M | $21.2M | ||
| Q3 24 | $36.3M | $24.2M | ||
| Q2 24 | $36.0M | $22.3M | ||
| Q1 24 | $35.6M | $15.6M |
净利润LAWRGNX
| Q4 25 | $-8.5M | $-67.1M | ||
| Q3 25 | $-13.7M | $-61.9M | ||
| Q2 25 | $-10.8M | $-70.9M | ||
| Q1 25 | $-11.4M | $6.1M | ||
| Q4 24 | $-25.2M | $-51.2M | ||
| Q3 24 | $-9.2M | $-59.6M | ||
| Q2 24 | $-10.8M | $-53.0M | ||
| Q1 24 | $-10.6M | $-63.3M |
毛利率LAWRGNX
| Q4 25 | 75.1% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.6% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 74.2% | 70.2% | ||
| Q3 24 | 73.1% | 48.8% | ||
| Q2 24 | 74.2% | 52.5% | ||
| Q1 24 | 75.1% | 72.6% |
营业利润率LAWRGNX
| Q4 25 | -22.4% | -190.0% | ||
| Q3 25 | -35.3% | -176.3% | ||
| Q2 25 | -31.0% | -296.3% | ||
| Q1 25 | -34.4% | 13.6% | ||
| Q4 24 | -70.6% | -242.1% | ||
| Q3 24 | -30.0% | -256.6% | ||
| Q2 24 | -34.4% | -251.3% | ||
| Q1 24 | -34.7% | -408.8% |
净利率LAWRGNX
| Q4 25 | -20.7% | -221.3% | ||
| Q3 25 | -33.4% | -208.3% | ||
| Q2 25 | -28.4% | -331.8% | ||
| Q1 25 | -31.1% | 6.8% | ||
| Q4 24 | -68.1% | -241.3% | ||
| Q3 24 | -25.3% | -246.3% | ||
| Q2 24 | -30.1% | -237.7% | ||
| Q1 24 | -29.7% | -405.4% |
每股收益（稀释后）LAWRGNX
| Q4 25 | $-0.13 | $-1.30 | ||
| Q3 25 | $-0.22 | $-1.20 | ||
| Q2 25 | $-0.18 | $-1.38 | ||
| Q1 25 | $-0.19 | $0.12 | ||
| Q4 24 | $-0.43 | $-0.99 | ||
| Q3 24 | $-0.15 | $-1.17 | ||
| Q2 24 | $-0.18 | $-1.05 | ||
| Q1 24 | $-0.17 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $114.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $128.1M | $102.7M |
| 总资产 | $173.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LAWRGNX
| Q4 25 | $114.6M | $230.1M | ||
| Q3 25 | $113.5M | $274.2M | ||
| Q2 25 | $114.5M | $323.3M | ||
| Q1 25 | $118.8M | $267.9M | ||
| Q4 24 | $129.1M | $234.7M | ||
| Q3 24 | $126.8M | $255.5M | ||
| Q2 24 | $130.0M | $290.4M | ||
| Q1 24 | $148.7M | $338.7M |
股东权益LAWRGNX
| Q4 25 | $128.1M | $102.7M | ||
| Q3 25 | $130.6M | $161.5M | ||
| Q2 25 | $137.9M | $213.7M | ||
| Q1 25 | $142.2M | $274.2M | ||
| Q4 24 | $147.5M | $259.7M | ||
| Q3 24 | $167.3M | $301.4M | ||
| Q2 24 | $170.9M | $348.3M | ||
| Q1 24 | $193.2M | $390.7M |
总资产LAWRGNX
| Q4 25 | $173.6M | $453.0M | ||
| Q3 25 | $174.8M | $525.2M | ||
| Q2 25 | $164.9M | $581.0M | ||
| Q1 25 | $168.0M | $490.9M | ||
| Q4 24 | $180.3M | $466.0M | ||
| Q3 24 | $194.4M | $519.1M | ||
| Q2 24 | $198.0M | $569.4M | ||
| Q1 24 | $217.3M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $762.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $255.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | 0.6% | -174.0% |
| 资本支出强度资本支出/营收 | 1.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LAWRGNX
| Q4 25 | $762.0K | $-52.3M | ||
| Q3 25 | $-979.0K | $-56.0M | ||
| Q2 25 | $-4.2M | $-49.3M | ||
| Q1 25 | $-10.5M | $33.6M | ||
| Q4 24 | $2.1M | $-31.6M | ||
| Q3 24 | $-2.9M | $-40.5M | ||
| Q2 24 | $-650.0K | $-45.5M | ||
| Q1 24 | $-7.3M | $-55.5M |
自由现金流LAWRGNX
| Q4 25 | $255.0K | $-52.8M | ||
| Q3 25 | $-2.0M | $-56.5M | ||
| Q2 25 | $-5.2M | $-49.7M | ||
| Q1 25 | $-11.0M | $32.6M | ||
| Q4 24 | $1.5M | $-32.7M | ||
| Q3 24 | $-3.7M | $-40.9M | ||
| Q2 24 | $-1.3M | $-46.0M | ||
| Q1 24 | $-8.0M | $-56.0M |
自由现金流率LAWRGNX
| Q4 25 | 0.6% | -174.0% | ||
| Q3 25 | -5.0% | -189.9% | ||
| Q2 25 | -13.6% | -232.8% | ||
| Q1 25 | -30.1% | 36.6% | ||
| Q4 24 | 4.1% | -154.2% | ||
| Q3 24 | -10.3% | -168.9% | ||
| Q2 24 | -3.6% | -206.2% | ||
| Q1 24 | -22.5% | -358.5% |
资本支出强度LAWRGNX
| Q4 25 | 1.2% | 1.7% | ||
| Q3 25 | 2.6% | 1.7% | ||
| Q2 25 | 2.5% | 1.8% | ||
| Q1 25 | 1.4% | 1.2% | ||
| Q4 24 | 1.5% | 5.1% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 1.8% | 2.1% | ||
| Q1 24 | 1.9% | 3.6% |
现金转化率LAWRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAW
| Software | $35.1M | 85% |
| Services | $6.0M | 15% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
